About this scholarly article

Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial by Baraliakos, X (author);Kivitz, Aj (author);Deodhar, Aa (author);Braun, J (author);Wei, JC (author);Delicha, Em (author);Talloczy, Z (author);Porter, B (author);Baraliakos, Xenofon (author);Kivitz, Alan J (author);Deodhar, Atul A (author);Braun, Jürgen (author);Wei, James C (author);Maria Delicha, Eumorphia (author);Talloczy, Zsolt (author);Porter, Brian (author);Ruhrgebiet, Rheumazentrum (author) is a scholarly article available to read on EtoBox.

Author

Baraliakos, X (author);Kivitz, Aj (author);Deodhar, Aa (author);Braun, J (author);Wei, JC (author);Delicha, Em (author);Talloczy, Z (author);Porter, B (author);Baraliakos, Xenofon (author);Kivitz, Alan J (author);Deodhar, Atul A (author);Braun, Jürgen (author);Wei, James C (author);Maria Delicha, Eumorphia (author);Talloczy, Zsolt (author);Porter, Brian (author);Ruhrgebiet, Rheumazentrum (author)